DexCom Inc (DXCM)vsLivaNova PLC (LIVN)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
LIVN
LivaNova PLC
$78.18
0.00%
HEALTHCARE · Cap: $4.50B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 238% more annual revenue ($4.97B vs $1.47B). DXCM leads profitability with a 20.1% profit margin vs 12.8%. LIVN appears more attractively valued with a PEG of 0.93. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
LIVN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
+7.7%
Fair Value
$71.98
Current Price
$78.18
$6.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Earnings expanding 287.8% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : LIVN
The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : LIVN
The primary concerns for LIVN are Altman Z-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while LIVN is a value play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 68/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?